| Title |
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
|
|---|---|
| Published in |
Clinical Pharmacology : Advances and Applications, December 2012
|
| DOI | 10.2147/cpaa.s26586 |
| Pubmed ID | |
| Authors |
Reena P Thomas, Lawrence Recht, Seema Nagpal |
| Abstract |
Glioblastoma (GB) is one of the most lethal forms of cancer, with an invasive growth pattern that requires the use of adjuvant therapies, including chemotherapy and radiation, to prolong survival. Temozolomide (TMZ) is an oral chemotherapy with a limited side effect profile that has become the standard of care in GB treatment. While TMZ has made an impact on survival, tumor recurrence and TMZ resistance remain major challenges. Molecular markers, such as O6-methylguanine-DNA methyltransferase methylation status, can be helpful in predicting tumor response to TMZ, and therefore guides clinical decision making. This review will discuss the epidemiology and possible genetic underpinnings of GB, how TMZ became the standard of care for GB patients, the pharmacology of TMZ, the practical aspects of using TMZ in clinic, and how molecular diagnostics - particularly the use of O6-methylguanine-DNA methyltransferase status - affect clinical management. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 2% |
| Brazil | 1 | 1% |
| Unknown | 85 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 22% |
| Student > Master | 15 | 17% |
| Student > Bachelor | 11 | 13% |
| Researcher | 10 | 11% |
| Student > Doctoral Student | 7 | 8% |
| Other | 9 | 10% |
| Unknown | 17 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 19% |
| Biochemistry, Genetics and Molecular Biology | 13 | 15% |
| Agricultural and Biological Sciences | 13 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 8% |
| Chemistry | 6 | 7% |
| Other | 14 | 16% |
| Unknown | 18 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2013.
All research outputs
#16,722,913
of 25,374,917 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#109
of 179 outputs
Outputs of similar age
#185,875
of 285,750 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#3
of 3 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 179 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,750 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.